The anticholinesterase phenserine and its enantiomer posiphen as 5′untranslated-region-directed translation blockers of the Parkinson's alpha synuclein expression

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Mikkilineni, Sohan ^a   Cantuti Castelvetri, Ippolita ^a   Cahill, Catherine M ^a   Balliedier, Amelie ^a   Greig, Nigel H ^b   Rogers, Jack T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MESSENGER RNA; PHENSERINE;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TRANSLATION REGULATION;

EID: 84862290233     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/142372     Document Type: Article

References (62)

1. Standaert G. S., Young A. B., Brunton L. L., Treatment of the central nervous system degenerative disorders Goodman Gilaman's The Pharmacological Basis of Therapeutics 2005 New York, NY, USA McGraw-Hill 527 545
2. DeLong M. R., Juncos J. L., Hauser S. L., Parkinson's disease and other movement disorders Harrison's Neurology in Clinical Medicine 2006 New York, NY, USA McGraw-Hill 295 314
3. Forno L. S., Neuropathology of Parkinson's disease Journal of Neuropathology and Experimental Neurology 1996 55 3 259 272 (Pubitemid 26085575)
4. Cantuti-Castelvetri I., Standaert D. G., Neuroprotective strategies for Parkinson's disease Current Neuropharmacology 2004 2 153 168
5. Chaudhuri K. R., Naidu Y., Early Parkinson's disease and non-motor issues Journal of Neurology 2008 255 5 33 38
6. Chaudhuri K. R., Odin P., The challenge of non-motor symptoms in Parkinson's disease Progress in Brain Research 2010 184 325 341
7. Chaudhuri K. R., Schapira A. H., Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment The Lancet Neurology 2009 8 5 464 474
8. Jellinger K. A., Synuclein deposition and non-motor symptoms in Parkinson disease Journal of the Neurological Sciences 2011 310 1 107 111
9. Claassen D. O., Josephs K. A., Ahlskog J. E., Silber M. H., Tippmann-Peikert M., Boeve B. F., REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century Neurology 2010 75 6 494 499
10. Postuma R., Gagnon J. F., Cognition and olfaction in Parkinson's disease Brain 2010 133 12 e160. author reply e161
11. Hely M. A., Reid W. G. J., Adena M. A., Halliday G. M., Morris J. G. L., The Sydney Multicenter Study of Parkinson's disease: the inevitability of dementia at 20 years Movement Disorders 2008 23 6 837 844
12. Reid W. G. J., Hely M. A., Morris J. G. L., Broe G. A., Adena M., Sullivan D. J. O., Williamson P. M., A longitudinal study of Parkinson's disease: clinical and neuropsychological correlates of dementia Journal of Clinical Neuroscience 1996 3 4 327 333 (Pubitemid 126658505)
13. Larner A., Cholinesterase inhibitors: beyond Alzheimer's disease Expert Review of Neurotherapeutics 2010 10 11 1699 1705
14. Olin J. T., Aarsland D., Meng X., Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living Dementia and Geriatric Cognitive Disorders 2010 29 6 510 515
15. Schmitt F. A., Aarsland D., Brnnick K. S., Xiangyi Meng, Tekin S., Olin J. T., Evaluating rivastigmine in mild-to-moderate Parkinsons disease dementia using ADAS-cog items American Journal of Alzheimer's Disease and other Dementias 2010 25 5 407 413
16. Schmitt F. A., Farlow M. R., Meng X., Tekin S., Olin J. T., Efficacy of rivastigmine on executive function in patients with parkinson's disease dementia CNS Neuroscience Therapeutics 2010 16 6 330 336
17. Burn D. J., The treatment of cognitive impairment associated with parkinson's disease Brain Pathology 2010 20 3 672 678
18. Greenamyre J. T., Hastings T. G., Parkinson'sdivergent causes convergent mechanisms Science 2004 304 5674 1120 1122
19. Gwinn-Hardy K., Genetics of parkinsonism Movement Disorders 2002 17 4 645 656 (Pubitemid 41295002)
20. Clayton D. F., George J. M., The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease Trends in Neurosciences 1998 21 6 249 254 (Pubitemid 28239982)
21. Polymeropoulos M. H., Lavedan C., Leroy E., Ide S. E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E. S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W. G., Lazzarini A. M., Duvoisin R. C., Di Iorio G., Golbe L. I., Nussbaum R. L., Mutation in the -synuclein gene identified in families with Parkinson's disease Science 1997 276 5321 2045 2047 (Pubitemid 27443610)
22. Polymeropoulos M. H., Autosomal dominant Parkinson's disease and alpha-synuclein Annals of Neurology 1998 44 3, supplement 1 S63 S64
23. Braak H., Del Tredici K., Rb U., De Vos R. A. I., Jansen Steur E. N. H., Braak E., Staging of brain pathology related to sporadic Parkinson's disease Neurobiology of Aging 2003 24 2 197 211 (Pubitemid 36007810)
24. Cahill C. M., Rogers J. T., Interleukin (IL) 1 induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/I B kinase pathway targeting activator protein-1 Journal of Biological Chemistry 2008 283 38 25900 25912
25. Wolozin B., Golts N., Iron and Parkinson's disease Neuroscientist 2002 8 1 22 32 (Pubitemid 34101815)
26. Gal S., Fridkin M., Amit T., Zheng H., Youdim M. B. H., M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease Journal of Neural Transmission, Supplement 2006 70 447 456 (Pubitemid 44622237)
27. Cahill C. M., Lahiri D. K., Huang X., Rogers J. T., Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases Biochimica et Biophysica Acta 2009 1790 7 615 628
28. Taylor J. P., Mata I. F., Farrer M. J., LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends in Molecular Medicine 2006 12 2 76 82 (Pubitemid 43202125)
29. Oakley A. E., Collingwood J. F., Dobson J., Love G., Perrott H. R., Edwardson J. A., Elstner M., Morris C. M., Individual dopaminergic neurons show raised iron levels in Parkinson disease Neurology 2007 68 21 1820 1825 (Pubitemid 46791395)
30. Weinreb O., Amit T., Mandel S., Youdim M. B. H., Neuroprotective molecular mechanisms of (-)-epigallocatechin-3-gallate: a reflective outcome of its antioxidant, iron chelating and neuritogenic properties Genes Nutrition 2009 4 4 283 296
31. Cantuti-Castelvetri I., Klucken J., Ingelsson M., Ramasamy K., McLean P. J., Frosch M. P., Hyman B. T., Standaert D. G., Alpha-synuclein and chaperones in dementia with Lewy bodies Journal of Neuropathology and Experimental Neurology 2005 64 12 1058 1066
32. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M. B. H., Weinreb O., Mandel S., Reduction of iron-regulated amyloid precursor protein and -amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease Journal of Neurochemistry 2006 97 2 527 536
33. Friedlich A. L., Tanzi R. E., Rogers J. T., The 5′-untranslated region of Parkinson's disease -synuclein messengerRNA contains a predicted iron responsive element [1] Molecular Psychiatry 2007 12 3 222 223 (Pubitemid 46328508)
34. Rogers J. T., Mikkilineni S., Cantuti-Castelvetri I., Smith D. H., Huang X., Bandyopadhyay S., Cahill C. M., Maccecchini M. L., Lahiri D. K., Greig N. H., The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen Journal of Neural Transmission 2011 118 3 493 507
35. Olivares D., Huang X., Branden L., Greig N. H., Rogers J. T., Physiological and pathological role of alpha-synuclein in parkinson's disease through iron mediated oxidative stress; the role of a putative iron-responsive element International Journal of Molecular Sciences 2009 10 3 1226 1260
36. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A. C., Kondo J., Ihara Y., Saitoh T., Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America 1993 90 23 11282 11286 (Pubitemid 23354413)
37. Lee V. M. Y., Giasson B. I., Trojanowski J. Q., More than just two peas in a pod: common amyloidogenic properties of tau and -synuclein in neurodegenerative diseases Trends in Neurosciences 2004 27 3 129 134 (Pubitemid 38251512)
38. Jensen P. H., Hojrup P., Hager H., Nielsen M. S., Jacobsen L., Olesen O. F., Gliemann J., Jakes R., Binding of Abeta to alpha- and beta-synucleins: identification of segments in alpha-synuclein/NAC precursor that bind Abeta and NAC Biochemical Journal 1997 323 2 539 546 (Pubitemid 27183142)
39. Conway K. A., Harper J. D., Lansbury P. T., Accelerated in vitro fibril formation by a mutant -synuclein linked to early-onset Parkinson disease Nature Medicine 1998 4 11 1318 1320 (Pubitemid 28512115)
40. Han Hogyu, Weinreb P. H., Lansbury P. T. Jr., The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chemistry Biology 1995 2 3 163 169
41. Trojanowski J. Q., Lee V. M. Y., Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain Parkinsonism Related Disorders 2001 7 3 247 251 (Pubitemid 32372507)
42. Rogers J. T., Randall J. D., Cahill C. M., Eder P. S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S. S., Utsuki T., Greig N. H., Lahiri D. K., Tanzi R. E., Bush A. I., Giordano T., Gullans S. R., An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript Journal of Biological Chemistry 2002 277 47 45518 45528 (Pubitemid 36159162)
43. Duce J. A., Tsatsanis A., Cater M. A., James S. A., Robb E., Wikhe K., Leong S. L., Perez K., Johanssen T., Greenough M. A., Cho H. H., Galatis D., Moir R. D., Masters C. L., McLean C., Tanzi R. E., Cappai R., Barnham K. J., Ciccotosto G. D., Rogers J. T., Bush A. I., Iron-Export Ferroxidase Activity of -Amyloid Precursor Protein is Inhibited by Zinc in Alzheimer's Disease Cell 2010 142 6 857 867
44. Davies P., Moualla D., Brown D. R., Alpha-synuclein is a cellular ferrireductase PLoS ONE 2011 6 1
45. Davies P., Wang X., Sarell C. J., Drewett A., Marken F., Viles J. H., Brown D. R., The synucleins are a family of redox-active copper binding proteins Biochemistry 2011 50 1 37 47
46. Lahiri D. K., Chen D., Maloney B., Holloway H. W., Yu Q. S., Utsuki T., Giordano T., Sambamurti K., Greig N. H., The experimental Alzheimer's Disease drug posiphen [(+)-phenserine] lowers amyloid- peptide levels in cell culture and mice Journal of Pharmacology and Experimental Therapeutics 2007 320 1 386 396 (Pubitemid 46025753)
47. Nakano I., Hirano A., Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease Annals of Neurology 1984 15 5 415 418 (Pubitemid 14145565)
48. Kuo Y. M., Li Z., Jiao Y., Gaborit N., Pani A. K., Orrison B. M., Bruneau B. G., Giasson B. I., Smeyne R. J., Gershon M. D., Nussbaum R. L., Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated -synuclein gene mutations precede central nervous system changes Human Molecular Genetics 2010 19 9 1633 1650
49. Ray B., Bailey J. A., Sarkar S., Lahiri D. K., Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: differential expression of neuronal and glial protein markers Journal of Neuroscience Methods 2009 184 2 294 302
50. Cho H. H., Cahill C. M., Vanderburg C. R., Scherzer C. R., Wang B., Huang X., Rogers J. T., Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1 Journal of Biological Chemistry 2010 285 41 31217 31232
51. Bandyopadhyay S., Huang X., Cho H., Greig N. H., Youdim M. B., Rogers J. T., Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5′untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator Journal of Neural Transmission, Supplement 2006 71 237 247 (Pubitemid 351412125)
52. Maccecchini M., Posiphens pharmacokinetics and mecha-883nism of action in mild cognitive impaired patients Alzheimers Dementia 2010 6 4, supplement 1 e54
53. Winblad B., Giacobini E., Frlich L., Friedhoff L. T., Bruinsma G., Becker R. E., Greig N. H., Phenserine efficacy in Alzheimer's disease Journal of Alzheimer's Disease 2010 22 4 1201 1208
54. Greig N. H., Sambamurti K., Yu Q. S., Brossi A., Bruinsma G. B., Lahiri D. K., An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease Current Alzheimer Research 2005 2 3 281 290 (Pubitemid 40980186)
55. Klein J., Phenserine Expert Opinion on Investigational Drugs 2007 16 7 1087 1097 (Pubitemid 47074163)
56. Shaw K. T. Y., Utsuki T., Rogers J., Yu Q. S., Sambamurti K., Brossi A., Ge Y. W., Lahiri D. K., Greig N. H., Phenserine regulates translation of -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development Proceedings of the National Academy of Sciences of the United States of America 2001 98 13 7605 7610 (Pubitemid 32567995)
57. Venti A., Giordano T., Eder P., Bush A. I., Lahiri D. K., Greig N. H., Rogers J. T., Integrated role of desferrioxamine and phenserine targeted to an iron-responsive element in the APP-mRNA 5′-untranslated region Annals of the New York Academy of Sciences 2004 1035 34 48 (Pubitemid 40362325)
58. Xia Y., Saitoh T., Uéda K., Tanaka S., Chen X., Hashimoto M., Hsu L., Conrad C., Sundsmo M., Yoshimoto M., Thal L., Katzman R., Characterization of the human -synuclein gene: genomic structure, transcription start site, promoter region and polymorphisms Journal of Alzheimer's Disease 2001 3 5 485 494 (Pubitemid 33031805)
59. Goforth J. B., Anderson S. A., Nizzi C. P., Eisenstein R. S., Multiple determinants within iron-responsive elements dictate iron regulatory protein binding and regulatory hierarchy RNA 2010 16 1 154 169
60. Luo W., Yu Q. S., Zhan M., Parrish D., Deschamps J. R., Kulkarni S. S., Holloway H. W., Alley G. M., Lahiri D. K., Brossi A., Greig N. H., Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine Journal of Medicinal Chemistry 2005 48 4 986 994 (Pubitemid 40270444)
61. Yu Q. S., Pei X. F., Holloway H. W., Greig N. H., Brossi A., Total syntheses and anticholinesterase activities of (3aS)-N(8)- norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues Journal of Medicinal Chemistry 1997 40 18 2895 2901 (Pubitemid 27382540)
62. Yu Q. S., Greig N. H., Holloway H. W., Brossi A., Syntheses and anticholinesterase activities of (3aS)-N1,N8- bisnorphenserine, (3aS)-N1,N8-bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine Journal of Medicinal Chemistry 1998 41 13 2371 2379 (Pubitemid 28285739)